Trial Profile
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 29 Dec 2021 Status changed from active, no longer recruiting to completed.
- 27 Oct 2020 Planned End Date changed from 31 May 2023 to 3 Nov 2021.
- 12 Dec 2017 Planned End Date changed from 1 Jun 2021 to 31 May 2023.